Biblio

Found 7 results
[ Author(Asc)] Keyword Title Type Year
Filters: First Letter Of Last Name is P and Author is Jacobus Pfisterer  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
P
J. Pfisterer, du Bois, A., Wagner, U., Quaas, J., Blohmer, J. - U., Wallwiener, D., Hilpert, F., and Group, A. Gynakologi, Docetaxel and carboplatin as first-line chemotherapy in patients with advanced gynecological tumors. A phase I/II trial of the Arbeitsgemeinschaft Gynakologische Onkologie (AGO-OVAR) Ovarian Cancer Study Group, Gynecol Oncol, vol. 92, pp. 949-56, 2004.
J. Pfisterer, Harter, P., Canzler, U., Richter, B., Jackisch, C., Hahmann, M., Hasenburg, A., Burges, A., Loibl, S., Gropp, M., Huober, J., Fink, D., du Bois, A., Committee, A. G. O. Ovarian, and Group, A. G. O. Ovarian Ca, The role of surgery in recurrent ovarian cancer, Int J Gynecol Cancer, vol. 15 Suppl 3, pp. 195-8, 2005.
J. Pfisterer, Plante, M., Vergote, I. B., du Bois, A., Hirte, H., Lacave, A. J., Wagner, U., Stähle, A., Stuart, G. C. E., Kimmig, R., Olbricht, S., Le, T., Emerich, J., Kuhn, W., Bentley, J., Jackisch, C., Luck, H. J., Rochon, J., Zimmermann, A. Hayden, Eisenhauer, E., -OVAR, A. G. O., -CTG, N. C. I. C., and -GCG, E. O. R. T. C., Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG, J Clin Oncol, vol. 24, pp. 4699-707, 2006.
J. Pfisterer, Weber, B., Reuss, A., Kimmig, R., du Bois, A., Wagner, U., Bourgeois, H., Meier, W., Costa, S., Blohmer, J. - U., Lortholary, A., Olbricht, S., Stähle, A., Jackisch, C., Hardy-Bessard, A. C., Möbus, V., Quaas, J., Richter, B., Schröder, W., Geay, J. - F., Luck, H. J., Kuhn, W., Meden, H., Nitz, U., Pujade-Lauraine, E., -OVAR, A. G. O., and , Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO, J Natl Cancer Inst, vol. 98, pp. 1036-45, 2006.
J. Pfisterer, Plante, M., Vergote, I. B., du Bois, A., Hirte, H., Lacave, A. J., Wagner, U., Stähle, A., Stuart, G. C. E., Kimmig, R., Olbricht, S., Le, T., Emerich, J., Kuhn, W., Bentley, J., Jackisch, C., Lück, H. - J., Rochon, J., Zimmermann, A. Hayden, and Eisenhauer, E., Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG., J Clin Oncol, vol. 24, no. 29, pp. 4699-707, 2006.
J. Pfisterer, Vergote, I. B., du Bois, A., and Eisenhauer, E., Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer., Int J Gynecol Cancer, vol. 15 Suppl 1, pp. 36-41, 2005.
J. Pfisterer, Weber, B., Reuss, A., Kimmig, R., du Bois, A., Wagner, U., Bourgeois, H., Meier, W., Costa, S., Blohmer, J. - U., Lortholary, A., Olbricht, S., Stähle, A., Jackisch, C., Hardy-Bessard, A. - C., Möbus, V., Quaas, J., Richter, B., Schröder, W., Geay, J. - F., Lück, H. - J., Kuhn, W., Meden, H., Nitz, U., and Pujade-Lauraine, E., Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO., J Natl Cancer Inst, vol. 98, no. 15, pp. 1036-45, 2006.